NASDAQ:IMMX

Immix Biopharma Stock Forecast, Price & News

$5.84

+0.01 (+0.17%)

(As of 01/14/2022 12:00 AM ET)

Add

Compare

Today's Range: $5.46
▼
$6.08
50-Day Range: N/A
52-Week Range: $2.85
▼
$8.68

Volume: 806,296 shs
Average Volume: 31.14 million shs
Market Capitalization: $44.24 million

P/E Ratio: N/A
Dividend Yield: N/A
Beta: N/A

30 days | 90 days | 365 days | Advanced Chart

Receive IMMX News and Ratings via Email

Sign-up to receive the latest news and ratings for Immix Biopharma and its competitors with MarketBeat's FREE daily newsletter.

About Immix Biopharma

Immix Biopharma Inc. is a biopharmaceutical company pioneering Tissue Specific Therapeutics (TM) targeting oncology and immuno-dysregulated diseases. Immix Biopharma Inc. is based in LOS ANGELES.

Immix Biopharma Inc's (NASDAQ:IMMX) Quiet Period To Expire on January 25th
January 18, 2022 | americanbankingnews.com

Immix Biopharma Inc Shares Close the Day 18.4% Higher - Daily Wrap
January 13, 2022 | nasdaq.com

Immix Reveals Data on Cancer Drug
January 12, 2022 | baystreet.ca

Immix Biopharma Spikes After IMX-110 Surpasses Standard Of Care In Mice Model
January 12, 2022 | nasdaq.com

Immix's Lead Program Shows 50% Response Rate In Resistant Cancer In Animal Study
January 12, 2022 | finance.yahoo.com

Immis Reveals Data on Cancer Drug
January 12, 2022 | baystreet.ca

ImmixBio jumps 42% after IMX-110 showed significant activity in soft tissue sarcoma study in mice
January 12, 2022 | seekingalpha.com

ImmixBio IMX-110 Produced 50% Positive Response Rate in First-Line-Therapy-Resistant Cancer, Surpassing the Standard of Care in Mice Study
January 12, 2022 | finance.yahoo.com

Immix Biopharma (NASDAQ:IMMX) Shares Down 9.8%
January 12, 2022 | americanbankingnews.com

Immix Biopharma Announces IMMX Investors Day to be Held on February 1, 2022 + Q&A Platform for All Shareholders
January 6, 2022 | finance.yahoo.com

Immix Biopharma continues hot streak; up 30% premarket
January 5, 2022 | seekingalpha.com

Immix Biopharma Soars On RPD for Pediatric Cancer Treatment
January 4, 2022 | finance.yahoo.com

Mid-Day Market Update: Gold Down 1%; Immix Biopharma Shares Spike Higher
January 3, 2022 | markets.businessinsider.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: N/A
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:IMMX
Previous Symbol
CUSIP: N/A
CIK: 1873835
Web: N/A
Phone: N/A
Fax: N/A
Employees: N/A
Year Founded: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Price-To-Earnings

Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A

Miscellaneous

Outstanding Shares: 7,575,000
Free Float: N/A
Market Cap: $44.24 million
Optionable: Not Optionable

Company Calendar

Today: 1/18/2022
Fiscal Year End: 12/31/2022

MarketRank^™

Overall MarketRank^™

0.00 out of 5 stars

Medical Sector

1399th out of 1,417 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Immix Biopharma.

0.0 Community Rank

Outperform Votes
Immix Biopharma has received 0 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Immix Biopharma has received 0 “underperform” votes. (Add your “underperform” vote.)

MarketBeat's community ratings are surveys of what our community members think about Immix Biopharma and other stocks. Vote “Outperform” if you believe IMMX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IMMX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Immix Biopharma does not currently pay a dividend.
Dividend Growth
Immix Biopharma does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Immix Biopharma insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

Immix Biopharma (NASDAQ:IMMX) Frequently Asked Questions

Who are some of Immix Biopharma's key competitors?: Some companies that are related to Immix Biopharma include CorMedix (CRMD), Sientra (SIEN), OncoCyte (OCX), TELA Bio (TELA), XpresSpa Group (XSPA), Silverback Therapeutics (SBTX), Celcuity (CELC), OptiNose (OPTN), DURECT (DRRX), Scancell (SCLP), CYBIN INC. (CYBN.NE) (CYBN), DarioHealth (DRIO), Procaps Group S.A (PROC), PAVmed (PAVM) and Apollo Endosurgery (APEN).
View all of IMMX's competitors.
When did Immix Biopharma IPO?: (IMMX) raised $23 million in an initial public offering on Thursday, December 16th 2021. The company issued 4,200,000 shares at $5.00-$6.00 per share.
What is Immix Biopharma's stock symbol?: Immix Biopharma trades on the NASDAQ under the ticker symbol "IMMX."
When does the company's quiet period expire?: Immix Biopharma's quiet period expires on Tuesday, January 25th. Immix Biopharma had issued 4,200,000 shares in its IPO on December 16th. The total size of the offering was $21,000,000 based on an initial share price of $5.00. During the company's quiet period, insiders and any underwriters involved in the IPO are restricted from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the expiration of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.
How do I buy shares of Immix Biopharma?: Shares of IMMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Immix Biopharma's stock price today?: One share of IMMX stock can currently be purchased for approximately $5.84.
How much money does Immix Biopharma make?: Immix Biopharma has a market capitalization of $44.24 million.

This page was last updated on 1/18/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms

Your Ultimate Investing Toolkit

Just $1.00 for your first month.